EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy and Safety of Vonoprazan vs Esomeprazole for Early Symptom Relief in Erosive Esophagitis: A 2-Week, Double-Blind Randomized Trial Using GerdQ

Ryan Herardi, Ari Fahrial Syam, Achmad Fauzi, Ikhwan Rinaldi, Amanda Pitarini Utari, Rangga Handika, Arlyando Saragih, Maulana Suryamin, Gerie Amarendra, Nikko Darnindro, Aru Ariadno, Zulfan Harahap und 3 weitere

Archives of Medical Science · 25.07.2026

DOI: 10.5114/aoms/220329 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Archives of Medical Science, online erschienen am 25.07.2026. Verfasst von Ryan Herardi und 14 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study compared the early symptom relief efficacy and safety of vonoprazan, a potassium-competitive acid blocker (P-CAB), and esomeprazole, a proton pump inhibitor (PPI), in patients with erosive esophagitis (EE). While PPIs are established treatments, P-CABs are a new option offering a faster onset of action. Material and methods In this multicenter, double-blind, randomized controlled trial, adults with Gastroesophageal Reflux Disease Questionnaire (GerdQ) scores ≥8 and endoscopy-confirmed EE received either vonoprazan 20 mg or esomeprazole 40 mg once daily for two weeks. The primary endpoint was complete resolution (CR) of symptoms at weeks 1 and 2 using GerdQ. Secondary endpoints included subgroup responses and safety.

Results

Among 216 participants (vonoprazan: 111; esomeprazole: 105), most had mild EE. At week 1, CR rates were 39.6% [95% CI: 31.0–48.9%] with vonoprazan and 42.9% [95% CI: 33.8–52.4%] with esomeprazole in the intention-to-treat (ITT) analysis, and 43.1% [95% CI: 33.9–52.8%] vs. 45.9% [95% CI: 36.4–55.8%] in the per-protocol (PP) analysis. At week 2, CR rates were 60.4% [95% CI: 51.1–69.0%] vs. 61.0% [95% CI: 51.4–69.7%] in ITT, and 66.3% [95% CI: 56.7–74.8%] vs. 66.0% [95% CI: 56.1–74.6%] in PP, with no significant between-group differences. Adverse events were similar, with nasopharyngitis, gastrointestinal symptoms, and headache/dizziness being the most frequent. No serious events occurred.

Conclusions

Vonoprazan and esomeprazole demonstrated similar efficacy and safety profiles for early symptom relief in patients with EE. Given these comparable outcomes, esomeprazole may represent a more economical initial option based on short-term medication costs. (ClinicalTrials.gov; NCT06720610).

Zitieren

APA

Herardi, R., Syam, A. F., Fauzi, A., Rinaldi, I., Utari, A. P., Handika, R., Saragih, A., Suryamin, M., Amarendra, G., Darnindro, N., Ariadno, A., Harahap, Z., Kurniawan, A., Sandra, S., & Arvant, A. Z. (2026). Efficacy and Safety of Vonoprazan vs Esomeprazole for Early Symptom Relief in Erosive Esophagitis: A 2-Week, Double-Blind Randomized Trial Using GerdQ. Archives of Medical Science. https://doi.org/10.5114/aoms/220329

Vancouver

Herardi R, Syam AF, Fauzi A, Rinaldi I, Utari AP, Handika R, et al. Efficacy and Safety of Vonoprazan vs Esomeprazole for Early Symptom Relief in Erosive Esophagitis: A 2-Week, Double-Blind Randomized Trial Using GerdQ. Archives of Medical Science. 2026. doi:10.5114/aoms/220329

BibTeX
@article{Herardi2026,
  author = {Herardi, Ryan and Syam, Ari Fahrial and Fauzi, Achmad and Rinaldi, Ikhwan and Utari, Amanda Pitarini and Handika, Rangga and Saragih, Arlyando and Suryamin, Maulana and Amarendra, Gerie and Darnindro, Nikko and Ariadno, Aru and Harahap, Zulfan and Kurniawan, Andry and Sandra, Sharon and Arvant, Anisya Zakiyyahaya},
  title = {Efficacy and Safety of Vonoprazan vs Esomeprazole for Early Symptom Relief in Erosive Esophagitis: A 2-Week, Double-Blind Randomized Trial Using GerdQ},
  journal = {Archives of Medical Science},
  year = {2026},
  doi = {10.5114/aoms/220329}
}
Kostenlos starten →